Comparison
Piracetam vs Coluracetam
Piracetam
The original nootropic, developed in 1964 by Romanian chemist Corneliu Giurgea. A cyclic derivative of GABA and the founding member of the racetam family.
Coluracetam
Choline-uptake enhancer with reported visual and color perception effects.
| Field | Piracetam | Coluracetam |
|---|---|---|
| Category | racetam | racetam |
| Dose range | 1200–4800mg | 5–20mg |
| Half-life | 5h | 3h |
| Onset | 45min | — |
| Evidence | EVIDENCEA | EVIDENCEC |
| Safety | ●●●●● | ●●●●○ |
| Legal (US) | USUnscheduled | USUnscheduled |
| PubMed refs | 1200 | 15 |
The comparison in plain English
Auto-generated from dataPiracetam and Coluracetam are both in the racetam category respectively. Piracetam The original nootropic, developed in 1964 by Romanian chemist Corneliu Giurgea. Coluracetam Choline-uptake enhancer with reported visual and color perception effects.
Bottom line
Piracetam (evidence A, safety 5/5) has a weaker evidence base than Coluracetam (evidence C, safety 4/5). Piracetam has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose Piracetam if
Piracetam is the better fit when your goal aligns with its mechanism (Modulates AMPA and NMDA glutamate receptors and enhances acetylcholine signaling via muscarinic receptor allosteric modulation) and the dose range (1200–4800mg) suits your protocol. Half-life is 5h.
Choose Coluracetam if
Coluracetam is the better fit when your goal aligns with its mechanism (Enhances high-affinity choline uptake selectively in damaged cholinergic neurons — preserving function in compromised tissue rather than upregulating healthy tissue) and the dose range (5–20mg) suits your protocol. Half-life is 3h.